TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38785314

Group type: EXPERIMENTAL
Intervention: Enhanced hydration (20 mL/kg body weight, one-third given via bolus and remainder over 8 hours)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard hydration (60 mL/h for 8 hours, followed by maintenance infusion of 40-80 mL/h for the subsequent 64 hours)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Enhanced hydration
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 488
Study: 38785405

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 38785484

Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac
Number of subjects: 23
Study: 38786455

Group type: EXPERIMENTAL
Intervention: Health education intervention (HEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator group (control)
Number of subjects: 0
Study: 38786579

Group type: EXPERIMENTAL
Intervention: Orsiro biodegradable polymer SES
Number of subjects: 328

Group type: COMPARATOR
Intervention: Coroflex ISAR polymer-free sirolimus-eluting stent
Number of subjects: 328
Study: 38787303

Group type: EXPERIMENTAL
Intervention: Auditory processing measures in the binaural domain
Number of subjects: 274

Group type: COMPARATOR
Intervention: Peripheral hearing
Number of subjects: 274
Study: 38787436

Group type: EXPERIMENTAL
Intervention: Time in tight range (TITR: 3.9-7.8 mmol/l)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Time in range (TIR: 3.9-10.0 mmol/l)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Increasing TITR/TIR quartiles
Number of subjects: 808
Study: 38787559

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise and pain neuroscience education
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pain neuroscience education alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 38787562

Group type: EXPERIMENTAL
Intervention: Remote, pushed digital assessments and engagement (monthly text messaging about mental health, mental health assessments, and linkages to care)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Usual care (open access to a web-based mental health platform)
Number of subjects: 1275
Study: 38787613

Group type: EXPERIMENTAL
Intervention: Mindfulness Ecological Momentary Intervention (EMI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Self-monitoring app
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mindfulness EMI
Number of subjects: 110
Study: 38787930

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 734
Study: 38788174

Group type: EXPERIMENTAL
Intervention: CT041 (CAR-modified T-cell therapy targeting claudin18.2)
Number of subjects: 24
Study: 38788175

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment in good-grade aSAH (N = 232)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Usual care in good-grade aSAH (N = 241)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment in poor-grade aSAH (N = 162)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Usual care in poor-grade aSAH (N = 176)
Number of subjects: 812
Study: 38788195

Group type: EXPERIMENTAL
Intervention: Anterior wall tumors (TURBT)
Number of subjects: 118477

Group type: EXPERIMENTAL
Intervention: Dome tumors (TURBT)
Number of subjects: 118477

Group type: COMPARATOR
Intervention: Dome tumors (Partial cystectomy)
Number of subjects: 118477

Group type: EXPERIMENTAL
Intervention: Anterior wall tumors (SEER cohort)
Number of subjects: 118477

Group type: EXPERIMENTAL
Intervention: Dome tumors (SEER cohort)
Number of subjects: 118477
Study: 38788261

Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1400
Study: 38788341

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - having fruits and vegetables (F&V) at home
Number of subjects: 964

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - increasing home availability of F&V
Number of subjects: 964

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - not having sweets or salty snacks available at home
Number of subjects: 964

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - having F&V availability
Number of subjects: 964

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - never having soft drinks at home
Number of subjects: 964

Group type: COMPARATOR
Intervention: Food Parenting Practices (FPPs) - never being permissive about soft drink consumption
Number of subjects: 964
Study: 38788664

Group type: EXPERIMENTAL
Intervention: BRV 50-200 mg/day
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 803
Study: 38788744

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir plus dolutegravir
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Dolutegravir with tenofovir disoproxil fumarate plus either lamivudine or emtricitabine
Number of subjects: 828

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir plus two NRTIs
Number of subjects: 828
Study: 38788821

Group type: EXPERIMENTAL
Intervention: TEER with MitraClip device plus guideline-directed medical therapy (GDMT)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Repeat mitral valve intervention (RMVI)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI
Number of subjects: 293

Group type: COMPARATOR
Intervention: Patients without RMVI
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI pre-RMVI
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Patients who underwent RMVI post-RMVI
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Rate ratio of HFH after RMVI
Number of subjects: 293
Study: 38788861

Group type: EXPERIMENTAL
Intervention: CT-P13 SC 120 mg every 2 weeks until week 54
Number of subjects: 944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 944
Study: 38788904

Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of 1 g of tranexamic acid (TXA) dissolved in 50 mL of 0.9% saline at multiple sites
Number of subjects: 60

Group type: COMPARATOR
Intervention: 60 mL saline injection (Control)
Number of subjects: 60
Study: 38788907

Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole 2.5 mg/day
Number of subjects: 617
Study: 38788915

Group type: EXPERIMENTAL
Intervention: Allogenic FMT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Autologous FMT
Number of subjects: 72
Study: 38789080

Group type: EXPERIMENTAL
Intervention: Post-trial follow-up survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 0
Study: 38789134

Group type: EXPERIMENTAL
Intervention: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g corresponding to 70 mg of elemental iron) once daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (similar in colour, smell, and size to ferrous iron) once daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38789142

Group type: EXPERIMENTAL
Intervention: Proactive e-alcohol therapy
Number of subjects: 379
Study: 38789325

Group type: EXPERIMENTAL
Intervention: CCTA-guided stent size
Number of subjects: 65

Group type: COMPARATOR
Intervention: OCT lumen-guided stent size
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 65
Study: 38789363

Group type: EXPERIMENTAL
Intervention: Maintenance of beta-blockers
Number of subjects: 1789
Study: 38789460

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy (gemcitabine and cisplatin plus pembrolizumab)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy (NAC-ICI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasma IL-9
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tumor IL-8 signature and stroma-rich subtype
Number of subjects: 39
Study: 38789602

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.03 mcg/kg/min)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Phenylephrine (0.4 mcg/kg/min)
Number of subjects: 196
Study: 38789635

Group type: COMPARATOR
Intervention: BI 685509 (1.0, 2.5, or 5.0 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: BI 685509 (1 mg qd, 2.5 mg bid, 5.0 mg qd, 3.0 mg tid, 4.0 mg tid)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BI 685509
Number of subjects: 84
Study: 38789642

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 38789656

Group type: EXPERIMENTAL
Intervention: Rose geranium in sesame oil (RG) nasal spray, administered twice daily for 2 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Isotonic saline (IS) nasal spray, administered twice daily for 2 weeks
Number of subjects: 106
Study: 38789848

Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788)
Number of subjects: 0
Study: 38789896

Group type: EXPERIMENTAL
Intervention: Peripheral-compartment-first technique
Number of subjects: 704
Study: 38789924

Group type: EXPERIMENTAL
Intervention: Giredestrant plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus optional endocrine therapy (ET)
Number of subjects: 812
Study: 38789927

Group type: EXPERIMENTAL
Intervention: NP-led implementation of the Cardiovascular Assessment Screening Program (CASP)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual care by nurse practitioners (control group)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: NP-led implementation of CASP
Number of subjects: 167
Study: 38789966

Group type: EXPERIMENTAL
Intervention: CCP clinical audits
Number of subjects: 2867

Group type: COMPARATOR
Intervention: VINCat Programme
Number of subjects: 2867
Study: 38789992

Group type: EXPERIMENTAL
Intervention: Autologous or allogenic adipose tissue mesenchymal stromal cells (AT-MSC) combined with tricalcium phosphate biomaterial
Number of subjects: 12

Group type: COMPARATOR
Intervention: Autologous bone marrow mesenchymal stem cells (BM-MSC)
Number of subjects: 12
Study: 38790007

Group type: EXPERIMENTAL
Intervention: Body fat percent in aSAH patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Body fat mass in aSAH patients
Number of subjects: 59
Study: 38790008

Group type: EXPERIMENTAL
Intervention: Opioid maintenance treatment (OMT)
Number of subjects: 131
Study: 38790040

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo-to-tofacitinib
Number of subjects: 269
Study: 38790045

Group type: EXPERIMENTAL
Intervention: Audit intervention and implementation support intervention
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Audit intervention only
Number of subjects: 10000

Group type: COMPARATOR
Intervention: No intervention offered
Number of subjects: 10000
Study: 38790057

Group type: EXPERIMENTAL
Intervention: APG-1387 and anti-PD-1 antibody
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: APG-1387
Number of subjects: 4

Group type: COMPARATOR
Intervention: Blocking IL-12 secretion
Number of subjects: 4
Study: 38790505

Group type: EXPERIMENTAL
Intervention: 14-week Mellow Babies programme
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (waiting list)
Number of subjects: 38
Study: 38790900

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting BiOSS LIM C stent
Number of subjects: 230

Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents (rDESs)
Number of subjects: 230
Study: 38793103

Group type: EXPERIMENTAL
Intervention: Music as a motivating factor to promote physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological signals measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation and physical activity promotion routines
Number of subjects: 0
Study: 38793748

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), administered intramuscularly 14 days apart
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline/placebo (two doses administered intramuscularly 14 days apart)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2)
Number of subjects: 75
Study: 38794639

Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet (KD) for 4 months
Number of subjects: 7
Study: 38794715

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (5:2 Diet) plus Mediterranean dietary pattern (IER + MED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Mediterranean dietary pattern with daily energy restriction (DER + MED)
Number of subjects: 0
Study: 38794734

Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA), isokinetic, and ultrasound parameters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phase angle (cut-off: 5.10° men)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peak torque, total work, and mean power in leg extension
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Forearm muscle thickness
Number of subjects: 50
Study: 38794741

Group type: EXPERIMENTAL
Intervention: Synbiotic treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 38794892

Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy in MagnetisMM-2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Elranatamab monotherapy in MagnetisMM-3
Number of subjects: 16
Study: 38794906

Group type: EXPERIMENTAL
Intervention: ACLR+LET
Number of subjects: 92

Group type: COMPARATOR
Intervention: ACLR
Number of subjects: 92
Study: 38794945

Group type: EXPERIMENTAL
Intervention: 532-nm potassium titanyl-phosphate (KTP) laser
Number of subjects: 35

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 35
Study: 38795055

Group type: EXPERIMENTAL
Intervention: Avenciguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38795087

Group type: EXPERIMENTAL
Intervention: Percutaneous LAAC using single (Watchman 2.5/FLX) and double (Amplatzer Cardiac Plug or Amulet) devices
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Percutaneous LAAC procedures
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Double-closure left atrial appendage devices
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) at baseline
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 1023
Study: 38795108

Group type: EXPERIMENTAL
Intervention: TEER + guideline-directed medical therapy (GDMT)
Number of subjects: 347

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 347
Study: 38795110

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 30
Study: 38795120

Group type: COMPARATOR
Intervention: Standard immunochemotherapy followed by rituximab maintenance (standard arm)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Standard immunochemotherapy followed by response-adapted post-induction management (experimental arm)
Number of subjects: 807
Study: 38795650

Group type: EXPERIMENTAL
Intervention: Spatial Description Model
Number of subjects: 103
Study: 38795703

Group type: EXPERIMENTAL
Intervention: COX inhibitors plus anti-PD-1 therapy
Number of subjects: 30
Study: 38795716

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 2 weeks
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Bimekizumab (all dosing regimens)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1014
Study: 38795719

Group type: EXPERIMENTAL
Intervention: Myval THV
Number of subjects: 768

Group type: COMPARATOR
Intervention: Contemporary THV
Number of subjects: 768
Study: 38795747

Group type: EXPERIMENTAL
Intervention: PACE eating behavior risk score
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 76

Group type: COMPARATOR
Intervention: Children with high maternal BMI (≥30 kg/m²)
Number of subjects: 76
Study: 38795859

Group type: EXPERIMENTAL
Intervention: Sarilumab (IL-6R blockade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38796193

Group type: EXPERIMENTAL
Intervention: Azacitidine (300 mg once a day for 14 days in a 28-day cycle)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Investigator's choice standard therapy (ICT; gemcitabine, bendamustine, or romidepsin)
Number of subjects: 86
Study: 38796326

Group type: EXPERIMENTAL
Intervention: High-dose rotavirus inactivated vaccine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Medium-dose rotavirus inactivated vaccine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose rotavirus inactivated vaccine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 38796422

Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT) for 6 cycles
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT for 6 cycles
Number of subjects: 47
Study: 38796495

Group type: EXPERIMENTAL
Intervention: AGuIX gadolinium-based nanoparticle
Number of subjects: 23
Study: 38796500

Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral antibiotics and mechanical bowel preparation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study: 38796564

Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Number of subjects: 0
Study: 38796619

Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept
Number of subjects: 159

Group type: COMPARATOR
Intervention: 2 mg Aflibercept
Number of subjects: 159
Study: 38796653

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 17604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study: 38796655

Group type: EXPERIMENTAL
Intervention: Clazakizumab (monoclonal antibody targeting IL-6 ligand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38797114

Group type: EXPERIMENTAL
Intervention: Nurse-led multidomain intervention including risk factors assessment, education, antiemetics, dietary strategies, and relaxation therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nurse-led multidomain intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care of CINV (control group)
Number of subjects: 92
Study: 38797183

Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week)
Number of subjects: 556

Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (two intramuscular injections at enrolment and at 2 months)
Number of subjects: 556

Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 556
Study: 38797190

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/kg intravenously on day 2 or 3, then once every 3 weeks for 2 years) + low-dose, single-fraction radiotherapy (8 Gy/1 fx)
Number of subjects: 25
Study: 38797460

Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin (Pen V arm, twice daily oral penicillin)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Benzathine Benzyl Penicillin G (BPG arm, every-28-day intramuscular penicillin)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin (Pen V arm)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Benzathine Benzyl Penicillin G (BPG arm)
Number of subjects: 1004
Study: 38797482

Group type: EXPERIMENTAL
Intervention: Lycopene-rich vegetable juice providing low (13.1 mg), medium (23.9 mg), and high (31.0 mg) daily total carotenoid doses for 8 weeks.
Number of subjects: 80
Study: 38797481

Group type: COMPARATOR
Intervention: CON (dry blend)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EXT (HME blend)
Number of subjects: 9
Study: 38797490

Group type: EXPERIMENTAL
Intervention: SDF + KI
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: SMART (SDF + KI + GIC)
Number of subjects: 112
Study: 38797635

Group type: EXPERIMENTAL
Intervention: Cardiac index-guided therapy (using intravenous fluids and dobutamine)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 318
Study: 38797767

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic one-trocar-assisted pyeloplasty (OTAP)
Number of subjects: 70
Study: 38797835

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate and energy-restricted (LCER) diet (Pharm-TCR: <50 g carbohydrates; ~850-1100 kcal/day; n=20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU; n=16)
Number of subjects: 36
Study: 38797872

Group type: EXPERIMENTAL
Intervention: EHR-integrated prognostic CDS
Number of subjects: 536

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 536
Study: 38797892

Group type: EXPERIMENTAL
Intervention: Mirikizumab (50-1,000 mg i.v. every 4 weeks for induction; 200 mg s.c. every 4 or 12 weeks for maintenance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0
Study: 38798356

Group type: EXPERIMENTAL
Intervention: mFCCA short version
Number of subjects: 318
Study: 38798396

Group type: EXPERIMENTAL
Intervention: Novel non-invasive biomarkers of GERD, BE, airway hyperreactivity (AHR), treatment efficacy, and severity of symptoms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of Reflux disease.
Number of subjects: 0
Study: 38798481

Group type: EXPERIMENTAL
Intervention: TARANG intervention (4-month intervention with light touch engagement of husbands, 4 sessions)
Number of subjects: 41
Study: 38798524

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 14 days
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1250